NCT00312754View on ClinicalTrials.gov

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

PHASE4TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
HIV Infections
Interventions
DRUG

Atazanavir

Trial Locations (6)

75651

Local Institution, Paris

75877

Local Institution, Paris

75908

Local Institution, Paris

75970

Local Institution, Paris

93009

Local Institution, Bobigny

94270

Local Institution, Le Kremlin-Bicêtre

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00312754 - A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome | Biotech Hunter | Biotech Hunter